Martine van Vugt
Director/Board Member chez SCANDION ONCOLOGY A/S
Postes actifs de Martine van Vugt
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GENMAB A/S | Corporate Officer/Principal | 29/03/2023 | - |
| Human Resources Officer | 01/01/2019 | 29/03/2023 | |
| TME PHARMA N.V. | Director/Board Member | 24/06/2021 | - |
| Independent Dir/Board Member | 24/06/2021 | - | |
| SCANDION ONCOLOGY A/S | Director/Board Member | 01/04/2022 | - |
| Independent Dir/Board Member | 01/04/2022 | - | |
Immagene BV
 Immagene BV Pharmaceuticals: MajorHealth Technology Immagene BV is a private biotech company based in the Netherlands that is dedicated to developing next-generation precision immuno-oncology treatments. Immagene is committed to transforming cancer treatment and has a focus on precision medicine. The Dutch company was founded on world-leading research from the Netherlands Cancer Institute and drug R & D expertise from industry veterans. The company was founded by Maarten Ligtenberg, Christian Blank, and Daniel Peeper, with Maarten Ligtenberg serving as the CEO since incorporation. | Director/Board Member | - | - |
| Hollandbio | Director/Board Member | - | - |
Historique de carrière de Martine van Vugt
Formation de Martine van Vugt
| University of Utrecht | Doctorate Degree |
| Wageningen University | Graduate Degree |
Statistiques
Internationale
| Pays-Bas | 5 |
| Danemark | 3 |
| Allemagne | 2 |
Opérationnelle
| Director/Board Member | 4 |
| Independent Dir/Board Member | 2 |
| Human Resources Officer | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GENMAB A/S | Health Technology |
| TME PHARMA N.V. | Health Technology |
| SCANDION ONCOLOGY A/S | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Hollandbio | |
Immagene BV
Immagene BV Pharmaceuticals: MajorHealth Technology Immagene BV is a private biotech company based in the Netherlands that is dedicated to developing next-generation precision immuno-oncology treatments. Immagene is committed to transforming cancer treatment and has a focus on precision medicine. The Dutch company was founded on world-leading research from the Netherlands Cancer Institute and drug R & D expertise from industry veterans. The company was founded by Maarten Ligtenberg, Christian Blank, and Daniel Peeper, with Maarten Ligtenberg serving as the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Martine van Vugt
- Expérience
